



GLOBAL JOURNAL OF MEDICAL RESEARCH: G
VETERINARY SCIENCE AND VETERINARY MEDICINE
Volume 15 Issue 3 Version 1.0 Year 2015
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Gamma Interferon Assay for Cellular Immune Response in Cattle Vaccinated With FMD Vaccine Adjuvanted with Different Montanide Oils

By Sonia Ahmed Rizk, Wael Mossad Gamal EL-Din, Safy Eldean Mahdy,
Ehab EL-Sayed Ibrahim & Hiam Mohamed Fakhry

Veterinary Serum and Vaccine Research Institute, Egypt

Abstract- Cell-mediated immunity is critical for the prevention and control of Foot and Mouth Disease (FMD). Despite significant advancements in modern vaccinology, inactivated whole virus vaccines for FMD remain the mainstay for prophylactic and emergency uses. Emergency vaccination as part of the control strategies against foot-and-mouth disease virus (FMDV) has the potential to limit virus spread and reduce large-scale culling. Many efforts are currently devoted to improve the immune responses and protective efficacy of these vaccines. Adjuvants, which are often used to potentiate immune responses, provide an excellent mean to improve the efficacy of FMD vaccines.

Aim: To evaluate three oil adjuvants namely: Montanide ISA- 206, ISA-201 and ISA- 61 for adjuvant potential in inactivated FMD vaccine by determination of the produced amounts of interferon-gamma (IFN-gamma) in cattle vaccinated with FMD trivalent vaccine adjuvanted with different Montanide oils using interferon-gamma Assay for evaluation of FMD virus-specific cell-mediated immunity.

GJMR-G Classification : NLMC Code: WA 360



Strictly as per the compliance and regulations of:



© 2015. Sonia Ahmed Rizk, Wael Mossad Gamal EL-Din, Safy Eldean Mahdy, Ehab EL-Sayed Ibrahim & Hiam Mohamed Fakhry. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gamma Interferon Assay for Cellular Immune Response in Cattle Vaccinated With FMD Vaccine Adjuvanted with Different Montanide Oils

Sonia Ahmed Rizk ^α, Wael Mossad Gamal EL-Din ^ο, Safy Eldean Mahdy ^ρ, Ehab EL-Sayed Ibrahim ^ω & Hiam Mohamed Fakhry [¥]

Abstract- Cell-mediated immunity is critical for the prevention and control of Foot and Mouth Disease (FMD). Despite significant advancements in modern vaccinology, inactivated whole virus vaccines for FMD remain the mainstay for prophylactic and emergency uses. Emergency vaccination as part of the control strategies against foot-and-mouth disease virus (FMDV) has the potential to limit virus spread and reduce large-scale culling. Many efforts are currently devoted to improve the immune responses and protective efficacy of these vaccines. Adjuvants, which are often used to potentiate immune responses, provide an excellent mean to improve the efficacy of FMD vaccines.

Aim: To evaluate three oil adjuvants namely: Montanide ISA-206, ISA-201 and ISA- 61 for adjuvant potential in inactivated FMD vaccine by determination of the produced amounts of interferon-gamma (IFN-gamma) in cattle vaccinated with FMD trivalent vaccine adjuvanted with different Montanide oils using interferon-gamma Assay for evaluation of FMD virus-specific cell-mediated immunity.

All of the prepared vaccines were capable of stimulating a systemic gamma interferon response. Montanide ISA-61 adjuvanted vaccine induced early response and produced higher IFN-gamma as compared to the two other adjuvants, while no systemic IFN-gamma was detected in plasma samples from the unvaccinated cattle.

Conclusion: Finally, conclusion from the obtained results through the present study it could be concluded that, all of the prepared vaccines were capable of stimulating a systemic gamma interferon response. Montanide ISA-61 adjuvanted vaccine induced early response, high cellular and humeral immunity and produced higher IFN-gamma as compared to the two other adjuvants, while no systemic IFN-gamma was detected in plasma samples from the unvaccinated cattle.

I. INTRODUCTION

Foot-and-mouth disease virus (FMDV) causes foot-and-mouth disease (FMD), a contagious and fatal disease in cloven-hoofed animals, characterized by vesicles in the mouth, tongue, hoofs, and nipples and increase in body temperature and appetite loss **Depa et al., (2012)**. the natural route of infection is via the upper respiratory tract or through ingestion of the

virus. Initial virus replication usually occurs in the pharyngeal epithelium resulting in primary vesicles **Alexandersen and Mowat (2005)**. Fever and viraemia can occur within 1–2 days resulting in virus excretion from the respiratory tract, faeces, urine, saliva, milk and semen. Virus entering the blood disseminates to various predilection sites such as the mouth and nose, hooves and also sometimes teats and udder, in which secondary vesicles occur, and from which further virus is released **Grubman (2005) and Diaz-San et al., (2009)**. The progress in FMD vaccine production was primarily directed towards safety of the vaccine, purity of the antigen, selection of proper adjuvant and endurance of immunity **Osama (1992)**. Adjuvants, also can prolong the immune response and stimulate specific components of the immune response either humoral or cell mediated immunity **Lombard et al., (2007) and Cao (2014)**. Currently, the double oil emulsion vaccines are preferred for FMD prevention as they can be used to protect all susceptible species, particularly during an outbreak situation **Cox and Barnett (2009)**. Also, the oil adjuvant vaccines generate higher and long lasting immune responses, and show less interference from maternal antibodies than the aqueous vaccines **Selim et al., (2010)**. In particular, the Montanide™ ISA series of oil-adjuvants (SEPPIC France) have shown superior efficacy for inactivated FMD vaccines in different susceptible animal species **Iyer et al., (2000)**. Recently, SEPPIC has developed a new adjuvants (Montanide ISA-201 and Montanide ISA-61) and claim that those adjuvants induce better immune responses (particularly CMI responses) **Seppic. Montanide ISA 201 VG-ready to use oil adjuvant for veterinary vaccines and Sébastien et al., (2013)**. The ability to stimulate cell-mediated immunity (CMI) and consequent inhibition of sub-clinical infection in ruminants or otherwise induction of sterile immunity is usually insufficient **Moonen et al., (2004)** Interferons belong to cytokines. They are glycoproteins with multifaceted signal effects on cellular functions among which the antiviral effects belong to the early and non-specific defense mechanisms of organisms against infections **Vilcek and Sen (1996)**.

Author ^α ^σ ^ρ ^ω [¥]: Veterinary serum and vaccine research Institute, Cairo, Egypt. e-mail: ehabelsayed@hotmail.com

Interferons (IFNs) are the first line of the host innate immune defense against important, derives from its immunostimulatory and immunomodulatory effects **Samuel (2001) and Delcenserie et al., (2008)**. The assay system has proven to be a rapid, sensitive and inexpensive method for measuring antigen specific cell-mediated reactivity when compared with the more traditional lymphocyte proliferation assay. The IFN-gamma assay is the first in-vitro cellular assay to be used as a routine diagnostic test in veterinary medicine **Rothel et al., (1992)**. The production of interferon-gamma by stimulated helper T lymphocytes regulates production of immunoglobulin in vaccinated animals **Green et al., (2015)**. IFN-gamma is a modulator of T-cell growth and functional differentiation. It is a growth-promoting factor for T-lymphocytes and potentiates the response of these cells to mitogens or growth factors. The production of IFN-gamma or IL-4 by subsets of helper T lymphocytes reciprocally regulates production of IgG2a and IgG1. The minimum detectable dose of IFN-gamma is typically less than 5 pg/ml **Cubillos et al., (2008) and Bucafusco et al., (2015)**, while the protective level is more than 38% Sample to Positive (SP %) **Gurung et al., (2014)**.

It has been suggested that cell-mediated immunity may be involved in the clearance viral infection so the importance of Interferon-Gamma (IFN-gamma) in the immune system stems in part from its ability to inhibit viral replication directly, but, most of persistent virus **lloft et al., (1997) and Childerstone et al., (1999)** and it has been hypothesised that the initiation of FMDV persistence is correlated with the amount of interferon produced in the cells **Phillips and Dinter (1963)**. FMDV strains modified by passage in alternate hosts or repeated passage in cell cultures have reduced virulence in cattle and, in contrast to more virulent wild-virus, will induce the production of interferon **Zhang et al., (2014)** with a correlation between lack of virulence in cattle and increased IFN production **Alexandersen et al.,(2002)**.

The present work aims to evaluate the FMD virus-specific cell-mediated immunity in cattle vaccinated with FMD vaccine adjuvanted with different Montanide oils using interferon-gamma Assay, in order to determine to any extent FMD trivalent vaccine is able to elicit a sterile immunity.

II. MATERIAL AND METHODS

a) Cell and virus

Baby Hamster Kidney cell line (BHK21) Clone 13 maintained in FMD Department, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo according to the technique described by **Macpherson and Stocher (1962)** using Eagl's medium with 8-10% sterile new bovine serum, obtained from Sigma, USA,

used for virus propagation and application of serum neutralization test.

b) Virus propagation and concentration

FMD viruses O PanAsia2, A/Iran 05 and SAT2/2012, are locally isolated strains of cattle origin. The viruses were typed at Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo and confirmed by Pirbright, International Reference Laboratories, United Kingdom. FMD viruses then concentrated using polyethylene glycol 600 (PEG-600) according to **Killington et al., (1996)**. The viral suspension was concentrated at 25,000 rpm, for 5 hours at 4°C in a high-speed centrifuge (Avanti J25, Beckman Coulter, and Fullerton, CA, USA), the virus in the bottom was removed and pooled. The virus was further concentrated in ultracentrifuge 35,000 rpm/min, 3 hours at 4°C, the viral pelted pooled and aliquots of the concentrated virus preserved at -80°C.

c) FMD viruses inactivation

The concentrated virus stock completely inactivated using Binary Ethyleneimine (BEI) according to **Bahnemann (1975)**, 1%M BEI in 0.2N NaOH was added to the virus suspension to give final concentration of 0.001M of BEI. The virus and BEI mixture were mixed well and the pH adjusted to 8.0 by sodium bicarbonate. The virus was placed in the incubator at 37°C for 24 hours for inactivation to occur. Sodium thiosulphate was added to give a final concentration of 2% to neutralize the BEI action. The killed vaccine kept at -80°C, to use in preparation of vaccine formulation with different Montanide Oil adjuvants (ISA 206,201 and 61) for animal immunization according to **FAO. (2012)**.

d) Montanide ISA 206

This is a mineral oil based adjuvant which has been developed for the manufacture of Water-in-Oil-in-Water (W/O/W) emulsions mixed with antigen 50% w/w. It was obtained from Seppic, Paris, France.

e) Montanide ISA 201

This is a mineral oil based adjuvant that has been developed for the manufacture of Water-in-Oil-in-Water (W/O/W) emulsions mixed with antigen 50% w/w. It was obtained from Seppic, Paris, France.

f) Montanide ISA 61

This is a mineral oil based adjuvant that has been developed for the manufacture of water-in-oil (W/O) emulsions mixed with antigen 60% w/w. It was obtained from Seppic, Paris, France.

g) Trivalent FMD vaccines preparation

i. FMD oil adjuvanted vaccine formulated with Montanide ISA 206

Formulation with oil phase carried out according to the method described by **Wael et al., (2014)**, where the oil phase consisted of Montnide ISA

206 mixed with the inactivated viruses as equal parts of an aqueous and oil phase (50% w/ w) and mixed thoroughly.

ii. *FMD oil adjuvanted vaccine formulated with Montanide ISA 201*

Formulation with oil phase carried out according to the method described by **Dar et al., (2013)** and **Ehab et al., (2015)** where the oil phase consisted of Montanide ISA 201 mixed with the inactivated viruses as equal parts of an aqueous and oil phase (50% w/ w) and mixed thoroughly.

iii. *FMD oil adjuvanted vaccine formulated with Montanide ISA 61*

Formulation with oil phase carried out according to the method described by **Gurung et al., (2014)** where the oil phase consisted of Montanide ISA 61 mixed with the inactivated viruses as 60% of an aqueous and oil phase (60% w/w) and mixed thoroughly.

h) *Animal groups*

Twelve calves (local breed) were clinically healthy and free from antibodies against FMD virus as proved by using SNT and ELISA were used in this study.

Calves used in experimental vaccination were classified into four groups:

Group A: (3 animals) inoculated subcutaneously (S/C) with 3ml of inactivated FMD vaccine djuvanted with Montanide oil ISA 206.

Group B: (3animals) inoculated subcutaneously (S/C) with 3ml of inactivated FMD vaccine adjuvant with Montanide oil ISA 201.

Group C: (3 animals) inoculated subcutaneously (S/C) with 3ml of inactivated FMD vaccine adjuvanted with Montanide oil ISA 61.

Group D: (3 animals) non vaccinated and used as control group.

i) *Samples collection*

Blood samples were collected on 3rd post vaccination every three days for 2 weeks and later every week up to 10 weeks. Serum samples were collected weekly post vaccination for one month then every 2 weeks post-vaccination till the end of experiment. The immune response was evaluated through the detection of INF-gamma and humoral immune level using Bovine IFN-gamma ELISA assays, SNT and ELISA.

i. *Detection of interferon gamma (IFN-gamma) using Bovine IFN-gamma ELISA kits*

It was applied according to **Barnett et al., (2004)**. The cytokine IFN-gamma was measured in plasma samples from all cattle groups at various time points before and following vaccination using Bovine IFN- γ ELISA kit (**Mabtech- Sweden – code/3115-1H-20**). High protein binding ELISA plates were coated with mAb bIFN- γ -1 diluted to 2 μ g/ml in PBS, PH 7.4, by adding 100 μ l/well incubated overnight 4-8°C according to the

manual technique. The plates were washed with PBS (200 μ l/well) before blocking with PBS containing 1% bovine serum albumin for 30 min at room temperature. Blocked plates then were washed five times with PBS containing 0.05% Tween 20(Incubation buffer).

Bovine IFN-gamma was prepared standard by reconstituting content of vial in 1ml PBS to give concentration of 0.5 μ g/ml and leaved at room temperature for 15 minutes, then vortex the tube and spin down and use immediately. Samples or standards diluted in incubation buffer added as 100 μ l/well and incubated for 2 hours at room temperature, then washed as before. Then 100 μ l/well of mAb PAN-biotin at 0.1g/ml in incubation buffer was added, incubated for 1 hour at room temperature and then washed as washing step. Then 100 μ l/well of Streptavidin-Horse Radish Peroxidase (Streptavidin-HRP) diluted 1:1000 in incubation buffer was added and incubated at room temperature for 1 hour.

Appropriate substrate solution was added as 100 μ l/well. Finally measured the optical density in an ELISA reader after suitable developing time, absorbance values were read at 492 nm and the results were calculated according to kits typical data. Optical density values were normalized across plates using the following calculation:

Sample-to positive (SP %) = [(Mean sample OD) – (Mean negative control OD) /[(Mean positive control OD) – (Mean negative control OD) × 100
Gurung et al., (2014).

ii. *Serum neutralization test (SNT)*

The test was performed by the microtechnique as described by **Ferreira (1976)** in flat bottom tissue culture microtitre plates.

iii. *Enzyme linked immunosorbent assay (ELISA)*

It was carried out according to the method described by **Voller et al., (1976)**.


Serum samples were examined for FMD viral specific IgG antibodies using in-house developed ELISA assay.

III. RESULTS

Table (1) : Typical data using Bovine IFN-gamma ELISA Kits.

Standard	Bovine IFN-gamma Concentration (pg/ml)	O.D. at 492 nm	Mean O.D. at 492 nm
1	1000.0	1.983 - 1.977	1.980
2	500.0	1.701 - 1.790	1.746
3	250.0	0.881 - 0.876	0.879
4	125.0	0.462 - 0.485	0.479
5	62.5	0.252 - 0.258	0.255
6	31.3	0.144 - 0.149	0.147
7	15.6	0.093 - 0.096	0.095
8	7.8	0.067 - 0.067	0.067
Blank	0	0.031 - 0.028	0.030

Chart (1) : Standard curve for typical data using Bovine IFN-gamma ELISA Kits



a) Interferon gamma (IFN-gamma) ELISA

The cell mediated response to inactivated trivalent FMD vaccine adjuvanted with different Montanide oils was evaluated by measuring of IFN-gamma in plasma of vaccinated and control cattle groups. IFN-gamma for Montanide ISA 206 group (Group A) detected at 7th day following vaccination. Mean IFN-gamma cons. was (200pg/ml), Optical density (O.D.) was 0.763 and SP% was (40%). The highest level was at 14th day, with a cons. of (450pg/ml) and O.D. of 1.572 and SP% (84%). It was at protective level (>38%) till 35 days post vaccination. **Tables (2)**

IFN-gamma for Montanide ISA 201 group (Group B) detected at 3rd day following vaccination. Mean IFN-gamma cons. was (200pg/ml), Optical density (O.D.) was 0.765 and SP% was (40%). The highest level was at 14th day, with a cons. of (500pg/ml) and O.D. of 1.743 and SP% (93%). It was at protective level (>38%) till 42 days post vaccination. **Tables (3)**

IFN-gamma for Montanide ISA 61 group (Group C) detected at 3rd day following vaccination. Mean IFN-gamma cons. was (250pg/ml), Optical density (O.D.) was as 0.881 and SP% was (46%). The highest level was at 14th day, with a cons. of (800pg/ml) and O.D. of

1.847 and SP% (97.5%). It was at protective level IFN-gamma level of was undetectable in (>38%) till 56 days post vaccination. **Tables (4)** plasma of control unvaccinated group (Group D).

Table (2) : Interferon gamma (IFN-gamma) responses in cattle vaccinated with inactivated trivalent FMD vaccine adjuvanted with MontanideISA 206 oil

Days	IFN-gamma	Vaccinated cattle				Mean Control group
		A1	A2	A3	Mean	
0	*cons.	0	0	0	0	0
	O.D	0.031	0.030	0.029	0.030	0.030
	**SP%	0%	0%	0%	0%	0%
3	□cons.	125.0	125.0	62.5	100	0
	O.D	0.462	0.462	0.258	0.394	0.030
	SP%	23%	23%	12%	19.5%	0%
7	□cons.	200.0	200	200	200	0
	O.D	0.761	0.765	0.763	0.763	0.030
	SP%	40%	40%	40%	40%	0%
10	□cons.	250.0	250.0	250.0	250.0	0
	O.D	0.881	0.881	0.881	0.881	0.030
	SP%	46%	46%	46%	46%	0%
14	□cons.	450	450	450	450	0
	O.D	1.572	1.572	1.572	1.572	0.030
	SP%	84%	84%	84%	84%	0%
21	□cons.	450	450	450	450	0
	O.D	1.572	1.572	1.572	1.572	0.030
	SP%	84%	84%	84%	84%	0%
28	□cons.	400	400	400	400	0
	O.D	1.402	1.400	1.401	1.400	0.030
	SP%	74%	74%	74%	74%	0%
35	□cons.	250.0	250.0	250.0	250.0	0
	O.D	0.881	0.881	0.881	0.881	0.030
	SP%	46%	46%	46%	46%	0%
42	□cons.	125.0	125.0	62.5	100	0
	O.D	0.462	0.462	0.258	0.394	0.030
	SP%	23%	23%	12%	20%	0%
49	□cons.	100	100	100	100	0
	O.D	0.396	0.392	0.394	0.394	0.030
	SP%	19.5%	19.5%	19.5%	19.5%	0%
56	□cons.	62.5	62.5	62.5	62.5	0
	O.D	0.258	0.254	0.256	0.256	0.030
	SP%	12%	12%	12%	12%	0%

*IFN-gamma cons. (pg/ml)

O.D. at492 nm

** Sample-to positive %

SP% protection cutoff > 38%

Table (3) : Interferon gamma (IFN-gamma) responses in cattle vaccinated with inactivated trivalent FMD vaccine adjuvanted with MontanideISA 201 oil

Days *	IFN-gamma	Vaccinated cattle				Mean Control group
		A1	A2	A3	Mean	
0	*cons.	0	0	0	0	0
	O.D	0.031	0.030	0.029	0.030	0.030
	**SP%	0%	0%	0%	0%	0%
3	□cons.	200.0	200	200	200	0
	O.D	0.764	0.765	0.766	0.765	0.030
	SP%	40%	40%	40%	40%	0%
7	□cons.	250.0	250.0	250.0	250.0	0
	O.D	0.881	0.881	0.881	0.881	0.030
	SP%	46%	46%	46%	46%	0%
10	□cons.	500.0	500	500	500	0
	O.D	1.745	1.742	1.742	1.743	0.030
	SP%	93%	93%	93%	93%	0%
14	□cons.	250.0	250.0	250.0	250.0	0
	O.D	0.881	0.881	0.881	0.881	0.030
	SP%	46%	46%	46%	46%	0%
21	□cons.	500.0	450	500.0	650	0
	O.D	1.742	1.572	1.742	1.685	0.030
	SP%	92%	83%	92%	89%	0%
28	□cons.	400	400	400	400	0
	O.D	1.402	1.402	1.402	1.402	0.030
	SP%	74%	74%	74%	74%	0%
35	□cons.	250.0	250.0	250.0	250.0	0
	O.D	0.881	0.881	0.881	0.881	0.030
	SP%	46%	46%	46%	46%	0%
42	□cons.	250.0	250.0	250.0	250.0	0
	O.D	0.881	0.881	0.881	0.881	0.030
	SP%	46%	46%	46%	46%	0%
49	□cons.	125.0	125.0	125.0	125.0	0
	O.D	0.460	0.462	0.464	0.462	0.030
	SP%	23%	23%	23%	23%	0%
56	□cons.	100	100	100	100	0
	O.D	0.392	0.394	0.396	0.394	0.030
	SP%	19.5%	19.5%	19.5%	19.5%	0%

*IFN-gamma cons. (pg/ml)

O.D. at492 nm

** Sample-to positive %

SP% protection cutoff > 38%

Table (4) : Interferon gamma (IFN-gamma) responses in cattle vaccinated with inactivated trivalent FMD vaccine adjuvanted with Montanide ISA 61oil.

Days *	IFN-gamma	Vaccinated cattle				Mean Control group
		A1	A2	A3	Mean	
0	*cons.	0	0	0	0	0
	O.D	0.030	0.030	0.030	0.030	0.030
	**SP%	0%	0%	0%	0%	0%
3	□cons.	250.0	250.0	250.0	250.0	0
	O.D	0.881	0.881	0.881	0.881	0.030
	SP%	46%	46%	46%	46%	0%
7	□cons.	500.0	500	500	500	0
	O.D	1.745	1.745	1.745	1.745	0.030
	SP%	93%	93%	93%	93%	0%
10	□cons.	1000	650	800	800	0
	O.D	1.981	1.673	1.887	1.847	0.030
	SP%	105%	88%	100%	97.5%	0%
14	□cons.	800	800	500.0	800	0
	O.D	1.887	1.887	1.750	1.841	0.030
	SP%	100%	100%	92%	97.5%	0%
21	□cons.	500.0	450	500.0	650	0
	O.D	1.742	1.572	1.742	1.685	0.030
	SP%	92%	83%	92%	89%	0%
28	□cons.	500.0	450	500.0	650	0
	O.D	1.742	1.572	1.742	1.685	0.030
	SP%	92%	83%	92%	89%	0%
35	□cons.	400	400	400	400	0
	O.D	1.402	1.400	1.401	1.400	0.030
	SP%	74%	74%	74%	74%	0%
42	□cons.	400	400	400	400	0
	O.D	1.402	1.400	1.401	1.400	0.030
	SP%	74%	74%	74%	74%	0%
49	□cons.	250.0	250.0	250.0	250.0	0
	O.D	0.881	0.881	0.881	0.881	0.030
	SP%	46%	46%	46%	46%	0%
56	□cons.	250.0	250.0	250.0	250.0	0
	O.D	0.881	0.881	0.881	0.881	0.030
	SP%	46%	46%	46%	46%	0%

*IFN-gamma cons. (pg/ml)

O.D. at492 nm

** Sample-to positive %SP% protection cutoff > 38%

b) Evaluation of humeral immune response in calves vaccinated with FMD vaccines using SNT against FMDV serotypes (O,A&SAT2)

The humeral immune response of calves vaccinated with trivalent FMD vaccines(formulated with Montanide oil ISA 206,201 and 61) using SNT for FMD virus showed that protective neutralizing serum antibody titer for Montanide ISA 206 started at the 2nd week post vaccination with average antibody titer of (1.5-1.6 & 1.5

log₁₀) for (O, A & SAT2) respectively. The obtained antibody titer reached to the peak level at 10th week post vaccination with average titers of (2.4 – 2.7 & 2.6 log₁₀). The protective neutralizing serum antibody titer for Montanide ISA 201 started at the 1st week post vaccination with average antibody titer of (1.5-1.6&1.5 log₁₀) for (O, A&SAT2) respectively. The obtained antibody titer reached to the peak level at 10th week post vaccination with average titers of (3.05– 3.1 & 3.05

log₁₀). The protective neutralizing serum antibody titer for Montanide ISA 61 started at the 1st week post vaccination with average antibody titer of (1.7, 1.8 & 1.7 log₁₀) for (O, A & SAT2) respectively. The obtained

antibody titer reached to the peak level at 10th week post vaccination with average titers of (3.1-3.4 & 3.1 log₁₀).
Tables (5)

Table (5) : Neutralizing antibody titers of calves vaccinated with inactivated trivalent FMD vaccine using SNT against FMDV serotype (O , A & SAT2).

Time post vaccination	SNT titers of vaccinated animal groups									Control group
	Group A (ISA 206)			Group B (ISA 201)			Group C (ISA 61)			
	O	A	SAT2	O	A	SAT2	O	A	SAT2	
0	0.15*	0.12	0.12	0.3	0.3	0.3	0.3	0.3	0.3	0.3
1 week	0.9	1.2	0.9	1.5	1.6	1.5	1.7	1.8	1.7	0.3
2 week	1.5	1.6	1.5	1.7	1.8	1.7	1.8	2.1	1.8	0.3
3 week	1.8	1.8	1.8	2.1	2.4	2.1	2.4	2.4	2.4	0.3
4 week	2.1	2.1	2.1	2.4	2.4	2.4	2.7	2.7	2.7	0.6
6 week	2.1	2.4	2.1	2.4	2.7	2.4	2.7	2.9	2.7	0.9
8 week	2.4	2.4	2.4	2.7	2.9	2.7	3.05	3.1	3.05	0.9
10 week	2.4	2.7	2.6	3.05	3.1	3.05	3.1	3.4	3.1	0.9
12 week	2.4	2.4	2.4	2.7	2.9	2.7	3.05	3.1	3.05	0.6
14 week	2.1	2.1	2.1	2.7	2.7	2.7	2.8	2.8	2.8	0.6
16 week	2.1	2.1	2.1	2.4	2.7	2.4	2.7	2.8	2.7	0.6
18 week	2.1	2.1	2.1	2.4	2.4	2.4	2.6	2.7	2.6	0.6
20 week	1.8	1.8	1.8	2.1	2.4	2.1	2.4	2.7	2.4	0.6
22 week	1.8	1.8	1.8	2.1	2.1	2.1	2.4	2.4	2.4	0.3
24 week	1.8	1.8	1.8	1.8	2.1	1.8	2.1	2.4	2.1	0.3

* = Antibody titers expressed as log₁₀ serum neutralizing antibody titer.

Protective level (1.5)

c) *Evaluation of humeral immune response in calves vaccinated with FMD vaccines using ELISA against FMDV. serotypes (O,A&SAT2)*

The protective antibody titer for FMD vaccine formulated with Montanide ISA 206 started at the 2st week post vaccination with average antibody titer of (1.40 -1.50 & 1.50 log₁₀) for O,A & SAT2 respectively . The obtained antibody titer reached to the peak level at 10th week post vaccination with average titers of (2.90 – 2.92 & 2.92 log₁₀) for (O, A & SAT2) respectively.

The protective antibody titer for Montanide ISA 201 started at the 1st week post vaccination with average antibody titer of (1.93 -1.95 & 1.93 log₁₀). The obtained antibody titer reached to the peak level at 10th week post vaccination with average titers of (3.12- 3.15 & 3.13 log₁₀). The protective neutralizing serum antibody titer for Montanide ISA 61 started at the 2nd week post vaccination with average antibody titer of (1.97- 1.99 & 1.96 log₁₀). The obtained antibody titer reached to the peak level at 10th week post vaccination with average titers of (3.32 -3.34 & 3.33 log₁₀).
Table (6).

Table (6) : Antibody titers of calves vaccinated with inactivated trivalent FMD vaccine using ELISA against FMDV serotype (O, A and SAT2).

Time post vaccination	ELISA titers of vaccinated animal groups									Control group
	Group A (ISA 206)			Group B (ISA 201)			Group C (ISA 61)			
	O	A	SAT2	O	A	SAT2	O	A	SAT2	
0	0.24*	0.27	0.27	0.18*	0.21	0.21	0.11	0.21	0.21	0.3
1 week	1.40	1.50	1.50	1.93	1.95	1.93	1.70	1.70	1.69	0.0
2 week	1.90	1.92	1.90	2.12	2.12	2.11	1.97	1.99	1.96	0.0
3 week	2.19	2.19	2.16	2.42	2.42	2.41	2.61	2.62	2.61	0.3
4 week	2.43	2.43	2.43	2.47	2.47	2.46	2.43	2.49	2.48	0.6
6 week	2.44	2.44	2.44	2.73	2.73	2.73	2.73	2.79	2.79	0.7
8 week	2.80	2.80	2.78	2.92	2.92	2.92	2.92	2.95	2.95	0.6
10 week	2.90	2.92	2.92	3.12	3.15	3.13	3.32	3.34	3.33	0.6

12 week	3.10	3.10	3.10	3.15	3.15	3.15	3.15	3.19	3.19	0.6
14 week	2.49	2.49	2.49	2.85	2.85	2.85	2.97	2.99	2.99	0.0
16 week	2.52	2.52	2.52	2.67	2.67	2.67	2.75	2.78	2.76	0.6
18 week	2.43	2.43	2.43	2.66	2.66	2.65	2.69	2.71	2.71	0.0
20 week	2.19	2.19	2.19	2.34	2.34	2.34	2.60	2.62	2.62	0.6
22 week	2.10	2.11	2.11	2.31	2.32	2.32	2.44	2.46	2.46	0.7
24 week	2.09	2.10	2.10	2.34	2.34	2.34	2.43	2.46	2.46	0.3

* = Antibody titers expressed as \log_{10} ELISA antibody titer

Protective level (1.9)

IV. DISCUSSION

The first use of an oil adjuvant inactivated FMD vaccine was stated by **Cunliffe and Graves (1963)**. Such vaccine was found to induce higher immune levels and protection in vaccinated cattle than that induced by the conventional aluminum hydroxide vaccines. So it could be considered an important tool in the control programs of FMD **Bahnemann and Mesquita (1987)** and **Iyer et al., (2000)**. An adjuvant may act in one or more of five ways, based on current knowledge; namely, immune-modulation, presentation, induction of CD8+cytotoxic T-lymphocyte (CTL) responses, targeting, and depot generation. Addition to that adjuvant plays an important role in production of different lympho-kines such as various interleukins and INF-gamma according to **Barnett et al., (2004)** and **Ebeid et al., (2011)**. The innate immune response induced by a viral infection in the upper respiratory tract, the macrophages present in the respiratory tract produce interferons (IFNs) upon stimulation of pattern recognizing surface receptors, causing alterations in local vascular walls, and providing recruitment and activating stimuli to antigen presenting cells and phagocytes **Wilkins and Gale (2010)**. IFNs are also known as viral IFNs and secreted by virus infected cells with the function of blocking spread of virus to uninfected cells and have an important role in the host response to FMDV **Summerfield et al., (2009)** and that the ability of the virus to induce an IFN response may be related to the pathogenicity of different isolates of FMDV **Santos et al., (2006)** and **Stenfeldt et al., (2011)**. To better characterize the immune response to FMD vaccines and to search for early markers predictive of induction of immune memory; must analyze the kinetics and magnitude of the antibody and cell-mediated immune responses to FMD vaccines and further characterization of the antigen-specific CD4+ T-cell response better to be attempt by measuring IFN-gamma production **Carr et al., (2013)**.

So, this study was performed for evaluation of FMD virus-specific cell-mediated immunity in cattle vaccinated with FMD vaccine adjuvanted with different Montanide oils using interferon-gamma Assay, in order to determine to any extent FMD trivalent vaccine is able to elicit a sterile immunity.

Table (1) and Chart (1) show the typical data using Bovine IFN-gamma ELISA Kits for 8 slandered solutions beside the blank one. Bovine IFN- gamma Concentration (pg/ml) with the respectively O.D. at 492 nm.

From **Tables (2, 3 and 4)** no systemic IFN-gamma was detected in plasma samples from the unvaccinated cattle. IFN-gamma for Montanise ISA 206 group (Group A) detected at 7th day following vaccination, that results agreed with **Stenfeldt et al., (2011)** who observed that within seven days of vaccination with FMD oil vaccine, IFN-gamma production was observed and supported with **Cavalcanti et al., (2012)** and **Bucafusco et al., (2015)** they found that on day 7 both CD4⁺ and CD8⁺ T cell populations produced IFN-gamma. The obtained results also in agreement in some points with **Habjanec et al., (2008)** who stated that ISA206 formulations were less effective in inducing INF-gamma. IFN-gamma for Montanise ISA 201 group (Group B) detected at 3rd day following vaccination and that results agreed with **Dar et al., (2013)** who observed that Montanide ISA-201 adjuvanted vaccine induced earlier and higher immune response in vaccinated animals, and supported with **Gurung et al., (2014)** who reported that vaccine formulation with the antigen and Montanide™ ISA 201 adjuvant produced strong specific IFN-gamma responses in a high proportion of the vaccinated animals. IFN-gamma for Montanide ISA 201 group (Group B) detected at 3rd day following vaccination and that results agreed with **Dar et al., (2013)** who observed that Montanide ISA-201 adjuvanted vaccine induced earlier and higher immune response in vaccinated animals, and supported with **Gurung et al., (2014)** who reported that vaccine formulation with the antigen and Montanide™ ISA 201VG adjuvant produced strong specific IFN-gamma responses in a high proportion of the vaccinated animals. The results also come parallel and in agreement with what obtained by **Dong et al., (2013)** who reported that the efficacy of the FMD vaccine emulsified with ISA 201 was better than which with ISA 206. IFN-gamma for Montanide ISA 61 group (Group C) detected at 3rd day following vaccination and that results agreed with **Gurung et al., (2014)** who observed that vaccine formulated with ISA 61 showed the highest specific IFN-gamma responses among the

different ISA oil formulations, which can be observed at 9 weeks post vaccination. The results also showed that great variation was observed between the vaccinated animal groups in INF-gamma production level depending on the adjuvant. From previous results, the quantity of IFN-gamma produced was significantly the highest in group (C) compared to the other groups from day 3 till day 63 post-vaccination. Also, the quantity of IFN- γ produced in the plasma samples from vaccinated animals was significantly higher than the quantity produced in the samples from the unvaccinated control animals. From tables (5 and 6) the results revealed that SNT and ELISA titers for different oil FMD vaccines agreed with **Dar et al., (2013)** who showed that Montanide ISA-201 adjuvanted vaccine induced earlier and higher neutralizing antibody responses as compared to the two other oil adjuvants, also were supported by **Parida et al., (2006)** who recorded that IFN- production assay could be used to support the established serological assays to confirm infection in a previously vaccinated herd. Our results also go in hand with the results obtained were consistent with the statement of **Hamblin et al., (1986)** who explained that the SNT measures those antibodies which neutralize the infectivity of FMD virion, while ELISA probably measure all classes of antibodies even those produced against incomplete and non-infectious virus.

The obtained results were in agreement with **Parida et al., (2006)** and **Barnett et al., (2004)** who showed that in a vaccine IFN-gamma response could be a useful indicator of the ability of a FMD vaccine to elicit a so-called sterile immunity in which subclinical infection is prevented. This early IFN-gamma production probably comes from NK cells activated by macrophage derived cytokines as part of the innate immune response.

Our results also were supported by **Wu et al., (2003)** and **Diaz-San et al., (2010)** who suggested that there is a complex interplay between IFN-induced immunomodulatory in protection of animals against FMDV.

Finally, conclusion from the obtained results through the present study it could be concluded that, all of the prepared vaccines were capable of stimulating a systemic gamma interferon response. Montanide ISA-61 adjuvanted vaccine induced early response, high cellular and humeral immunity and produced higher IFN-gamma as compared to the two other adjuvants, while no systemic IFN-gamma was detected in plasma samples from the unvaccinated cattle.

REFERENCES RÉFÉRENCES REFERENCIAS

- Alexandersen, S., Zhang, Z. and Donaldson, A.I. (2002):** Aspects of the persistence of foot-and-mouth disease virus in animals—the carrier problem. *Microbes Infect.*; 4: 1099–1110.
- Alexandersen S, Mowat N. (2005):** Foot-and-mouth disease: host range and pathogenesis. *Curr. Top. Microbiol. Immunol.* 288: 9–42. And persistent infection *Plos One* 2012; 7(9): e44365.
- Bahnemann H. G. (1975).** Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. *Arch Virol* 47, 47–56.
- Bahnemann, H. G. and J. A. Mesquita. (1987):** Oil-adjuvant vaccine against foot-and-mouth disease. *Boletin del Centro Panamericano Fiebre Aftosa* 53: 25-30.
- Barnett PV, Keel P, Reid S, Armstrong RM, Statham RJ, Voyce C, Aggarwal N, Cox SJ. (2004):** Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the "carrier" state in sheep. *Vaccine* 12; 22 (9-10): 1221-32.
- Bucafusco D, Di Giacomo S, Pega J, Schammas JM, Cardoso N, Capozzo AV, Perez-Filgueira M. (2015):** Foot-and-mouth disease vaccination induces cross-reactive IFN- γ responses in cattle that are dependent on the integrity of the 140S particles. *Virology*; 476:11-8.
- Cao, Y. (2014):** Adjuvants for foot-and-mouth disease virus vaccines: recent progress *Expert Rev Vaccines.*; 13(11): 1377-85.
- Carr BV, Lefevre EA, Windsor MA, Inghese C, Gubbins S, Prentice H, Juleff ND, Charleston B. (2013):** CD4+ T-cell responses to foot-and-mouth disease virus in vaccinated cattle. *J. Gen Virol.* 94 (Pt 1): 97-107
- Cavalcanti YV, Brelaz MC, Neves JK, Ferraz JC, Pereira VR.; (2012):** Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis. *Pulm Med* 2012; 2012: 745483.
- Childerstone AJ, Cedillo-Baron L, Foster-Cuevas M, Parkhouse RM (1999):** Demonstration of bovine CD8+ T-cell responses to foot-and-mouth disease virus. *J Gen Virol* 80(Pt 3): 663–669.
- Cox, S. J. and Barnett, P. V. (2009):** Experimental evaluation of foot-and mouth disease vaccines for emergency use in ruminants and pigs. *Vet. Res. Vet.*, 40 (3) :13.
- Cubillos C, de la Torre BG, Jakab A, Clementi G, Borrás E, Barcena J, Andreu D, Sobrino F, Blanco E., (2008):** Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide. *Journal of Virology*, 82, 7223-7230.
- Cunliffe HR, Graves JH. (1963):** Formalin-Treated Foot-and-Mouth Disease Virus: Comparison of Two Adjuvants in Cattle. *Can J Comp Med Vet Sci.* 1963 Aug; 27(8):193-7.
- Dar P, Kalaivanan R, Sied N, Mamo B, Kishore S, Suryanarayana VV, Kondabattula G. (2013):**

- Montanide ISA™ 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle. *Vaccine* 2013 Jul 18; 31(33):3327-32.
15. **Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D. (2008):** Immunomodulatory effects of probiotics in the intestinal tract. *Curr Issues Mol Biol.*; 10(1-2):37-54.
 16. **Depa, P.M., Dimri, U., Sharma, M.C. and Tiwari, R. (2012)** Update on epidemiology and control of foot and mouth disease – A menace to international trade and global animal enterprise. *Vet. World*, 5(11): 694-704.
 17. **Diaz-San Segundo, F., T. Rodriguez-Calvo, A. de Avila, and N. Sevilla. (2009):** Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by IL-10.
 18. **Diaz-San Segundo, F., Moraes, M.P., de Los Santos, T., Dias, C.C. and Grubman, M.J.(2010):**Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression. *J. Virol.*; 84(4): 2063-2077.
 19. **Dong Li, Chunxue Zhou, Daliang She, Pinghua Li, Pu Sun, Xingwen Bai, Yingli Chen, Baoxia Xie, Zaixin Liu (2013):** The comparison of the efficacy of swine FMD vaccine emulsified with oil adjuvant of ISA 201 VG or ISA 206 VG. *Journal of Biosciences and Medicines*, 2013, 1, 22-25
 20. **Ebeid, M., Hamouda, F.K., Farag, M., Mahdy, S.E. (2011):** Emergency vaccination of cattle against foot-and-mouth disease confers complete clinical protection in 7 days and partial protection in 4 days. 4th Sci. Conf., Al-Kasr 25-28 Fac. Vet. Med., Benha University, Egypt.
 21. **Ehab El-sayed Ibrahim.,Wael Mossad Gamal., Amr Ismail Hassan., Safy El-Din Mahdy., Akram Zakaria. and Magdy Mahmoud Abdel-Atty. (2015)** Comparative study on the immuno-potentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent FMD vaccine. *Vet. World*, under press.
 22. **FAO. (2012)** Foot-and-mouth disease caused by serotype SAT2 in Egypt and Libya: A regional concern for animal health in North Africa and the Middle East "EMPRES WATCH, vol.25, March 2012, Rome.
 23. **Ferreira M.E.V. (1976) :** Prubade microneutralization poraestudies de anticueropos de la fibrea fsta 13th Centropanamericano Fiebre Aftosa, (21/22): 17-24. *Front Cell Infect Microbiol.* 16; 4:93.
 24. **Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Del Sorbo M, Angus B, Siani L, Di Marco S, Traboni C, Folgori A, Colloca S, Capone S, Vitelli A, Cortese R, Klenerman P, Nicosia A, Pollard AJ.(2015):** Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. *Sci Trasl Med* 12; 7(300):300ra126.
 25. **Grubman, M.J. (2005):** Development of novel strategies to control foot-and mouth disease marker vaccines and antivirals. *Biologicals*, 33:227-234.
 26. **Gurung RB, Purdie AC, Whittington RJ, Begg DJ. (2014):** Cellular and humoral immune responses in sheep vaccinated with candidate antigens MAP2698c and MAP3567 from *Mycobacterium avium* subspecies paratuberculosis.
 27. **Habjanec L, Halassy B, Tomasić J.(2008):** Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer. *Int Immunopharmacol.*; 8(5): 717-24.
 28. **Hamblin, C., Barnett IT and Hedger RS. (1986):** A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-and-mouth disease virus. I. Development and method of ELISA. *J Immunol Methods.*; 93(1):115-21.
 29. **Ilott MC, Salt JS, Gaskell RM, Kitching RP (1997):** Dexamethasone inhibits virus production and the secretory IgA response in oesophageal-pharyngeal fluid in cattle persistently infected with foot-and-mouth disease virus. *Epidemiol Infect* 118: 181–187.
 30. **Iyer, A.V.; Ghosh, S.; Singh, S.N.; Deshmukh, R.A. (2000):** "Evaluation of three ready to formulate oil adjuvants for foot and mouth disease vaccine production". *Vaccine*, 19(9-10): 1097-1105.
 31. **Killington, R. A., Stokes, A. & Hierholzer, J. C. (1996):** Virus purification. In *Virology Methods Manual*, pp. 73–74. Edited by B. W. J. Mahy & H. O. Kangro. New York: Academic Press
 32. **Lombard, M.; Pastoret, P. P. and Moulin, A.M. (2007):** A brief history of vaccines and vaccination. *Rev. Sci. Tech.* 26 (1):29-48.
 33. **Macpherson, M., Stocher, B., (1962):** Polyma transformation hamster cell clones, an investigation of genetic factors affecting cell competence. *Virology*, 16: 147-151.
 34. **Moonen, P., Jacob, L., CrienemA. And Dekker, A. (2004):** Detection of carriers of foot-and-mouth disease virus among vaccinated cattle. *Vet Microbiol.* 15; 103(3-4):151-60.
 35. **Oh Y, Fleming L, Statham B, Hamblin P, Barnett P, Paton DJ, Park JH, Joo YS, Parida S.(2012):** Interferon-γ induced by in vitro re-stimulation of CD4+ T-cells correlates within vivo FMD vaccine induced protection of cattle against disease **Osama, H.R. (1992):** Studies on inactivated Foot and Mouth Disease virus vaccine.
 36. **Parida S, Oh Y, Reid SM, Cox SJ, Statham RJ, Mahapatra M, Anderson J, Barnett PV, Charleston B, Paton DJ. (2006):** Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and

- infected cattle after incubation with inactivated FMDV. *Vaccine* 13; 24 (7): 964-9.
37. **Phillips L, Dinter Z (1963)**: The role of interferon in persistent infection with foot-and mouth disease virus. *J Gen Microbiol* 32: 277-285
 38. **Rothel JS, Jones SL, Corner LA, Cox JC, Wood PR. (1992)**: The gamma-interferon assay for diagnosis of bovine tuberculosis in cattle: conditions affecting the production of gamma-interferon in whole blood culture. *Aust Vet J.* 1992 Jan; 69(1):1-4.
 39. **Samuel, C. E. (2001)**: Antiviral actions of interferons. *Clin. Microbiol. Rev.* 14:778-809.
 40. **Santos de Los T, de Avila BS, Weiblen R, Grubman MJ. (2006)**: The leader proteinase of foot-and-mouth disease virus inhibits the induction of beta interferon mRNA and blocks the host innate immune response. *J Virol.* 2006;80:1906-1914
 41. **Sébastien Deville, Juliette Ben Arous, François Bertrand, Laurent Dupuis: (2013)** Montanide™ adjuvants for stimulation of cellular immune response in FMD vaccines *Tech Bull.* Paris: Seppic.
 42. **Selim A.M.A.; Abouzeid N.Z.; Aggour A.M. and Sobhy N.M.(2010)**: Comparative Study for Immune Efficacy of Two Different Adjuvants Bivalent FMD Vaccines in Sheep. *Journal of American Science*, 6 (10), 1292-1298.
 43. **Seppic. Montanide ISA 201 VG-ready to use oil adjuvant for veterinary vaccines.** *Tech Bull* 2008. Paris: Seppic.
 44. **Stenfeldt C, Heegaard PM, Stockmarr A, Tjørnehoj K, Belsham GJ (2011)**: Analysis of the acute phase responses of serum amyloid A, haptoglobin and Type 1 Interferon in cattle experimentally infected with foot-and-mouth disease virus serotype O. *Veterinary Research* 42, 66
 45. **Summerfield A, Guzylack-Piriou L, Harwood L, McCullough KC. (2009)** Innate immune responses against foot-and-mouth disease virus: current understanding and future directions. *Vet Immunol Immunopathol*; 128: 205-210.
 46. **Vilcek, J., and Sen, G.C. (1996)**: Interferons and other cytokines, in *Fields Virology* Philadelphia, PA., p. 375-399. *VMVSc Thesis (Virology)*, University of Cairo.
 47. **Voller A., Bidwell D.E. and Ann Bartlett (1976)**: Enzyme immune assay in diagnostic medicine, theory and practice. *Bull. World Health Org.*, 53: 55-65.
 48. **Wael Mossad Gamal El-Din, Ehab El-Sayed Ibrahim*, Hind Daoud and Samir Mohamed Ali (2014)**: Humeral and cellular immune response of Egyptian trivalent foot and mouth disease oil vaccine in sheep. *Res. Opin. Anim. Vet. Sci.*, 2014, 4(4), 178-185.
 49. **Wilkins, C. and Gale, M. Jr.(2010)**: Recognition of viruses by cytoplasmic sensors. *Curr Opin Immunol.* ;22: 41-47.
 50. **Wu, Q., Brum, M.C., Caron, L., Koste, r M. and Grubman, M.J. (2003)**: Adenovirus-mediated type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus. *J .Interferon Cytokine Res.*;23(7):359-68.
 51. **Zhang C, Wang Y, Wang M, Su X, Lu Y, Su F, Hu S. (2014)**: Rapeseed oil and ginseng saponins work synergistically to enhance Th1 and Th2 immune responses induced by the foot-and-mouth disease vaccine. *Clin Vaccine Immunol*; 21 (8): 1113-9.